A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia.

Trial Profile

A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination With Vincristine/Doxorubicin/Dexrazoxane, in Children With Relapsed/Refractory Solid Tumors or Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Obatoclax (Primary) ; Dexrazoxane; Doxorubicin; Vincristine
  • Indications Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 23 May 2012 Planned end date changed from 1 Mar 2011 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top